328 related articles for article (PubMed ID: 25588723)
21. Effect of the STAT3 inhibitor STX-0119 on the proliferation of cancer stem-like cells derived from recurrent glioblastoma.
Ashizawa T; Miyata H; Iizuka A; Komiyama M; Oshita C; Kume A; Nogami M; Yagoto M; Ito I; Oishi T; Watanabe R; Mitsuya K; Matsuno K; Furuya T; Okawara T; Otsuka M; Ogo N; Asai A; Nakasu Y; Yamaguchi K; Akiyama Y
Int J Oncol; 2013 Jul; 43(1):219-27. PubMed ID: 23612755
[TBL] [Abstract][Full Text] [Related]
22. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment.
van Tellingen O; Yetkin-Arik B; de Gooijer MC; Wesseling P; Wurdinger T; de Vries HE
Drug Resist Updat; 2015 Mar; 19():1-12. PubMed ID: 25791797
[TBL] [Abstract][Full Text] [Related]
23. Evidence for the efficacy of disulfiram and copper combination in glioblastoma multiforme - A propos of a case.
Karamanakos PN; Trafalis DT; Papachristou DJ; Panteli ES; Papavasilopoulou M; Karatzas A; Kardamakis D; Nasioulas G; Marselos M
J BUON; 2017; 22(5):1227-1232. PubMed ID: 29135106
[TBL] [Abstract][Full Text] [Related]
24. Advances in histone deacetylase inhibitors in targeting glioblastoma stem cells.
Reddy RG; Bhat UA; Chakravarty S; Kumar A
Cancer Chemother Pharmacol; 2020 Aug; 86(2):165-179. PubMed ID: 32638092
[TBL] [Abstract][Full Text] [Related]
25. Drug Repurposing for Glioblastoma and Current Advances in Drug Delivery-A Comprehensive Review of the Literature.
Alomari S; Zhang I; Hernandez A; Kraft CY; Raj D; Kedda J; Tyler B
Biomolecules; 2021 Dec; 11(12):. PubMed ID: 34944514
[TBL] [Abstract][Full Text] [Related]
26. Targeting ALDH2 with disulfiram/copper reverses the resistance of cancer cells to microtubule inhibitors.
Wang NN; Wang LH; Li Y; Fu SY; Xue X; Jia LN; Yuan XZ; Wang YT; Tang X; Yang JY; Wu CF
Exp Cell Res; 2018 Jan; 362(1):72-82. PubMed ID: 29155365
[TBL] [Abstract][Full Text] [Related]
27. Blockade of TGF-β signaling by the TGFβR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma.
Zhang M; Kleber S; Röhrich M; Timke C; Han N; Tuettenberg J; Martin-Villalba A; Debus J; Peschke P; Wirkner U; Lahn M; Huber PE
Cancer Res; 2011 Dec; 71(23):7155-67. PubMed ID: 22006998
[TBL] [Abstract][Full Text] [Related]
28. Glioblastoma: therapeutic challenges, what lies ahead.
Lima FR; Kahn SA; Soletti RC; Biasoli D; Alves T; da Fonseca AC; Garcia C; Romão L; Brito J; Holanda-Afonso R; Faria J; Borges H; Moura-Neto V
Biochim Biophys Acta; 2012 Dec; 1826(2):338-49. PubMed ID: 22677165
[TBL] [Abstract][Full Text] [Related]
29. Repurposing drugs for glioblastoma: From bench to bedside.
Basso J; Miranda A; Sousa J; Pais A; Vitorino C
Cancer Lett; 2018 Aug; 428():173-183. PubMed ID: 29729291
[TBL] [Abstract][Full Text] [Related]
30. Repurposing Disulfiram for Targeting of Glioblastoma Stem Cells: An In Vitro Study.
Zirjacks L; Stransky N; Klumpp L; Prause L; Eckert F; Zips D; Schleicher S; Handgretinger R; Huber SM; Ganser K
Biomolecules; 2021 Oct; 11(11):. PubMed ID: 34827559
[TBL] [Abstract][Full Text] [Related]
31. Personalized regulation of glioblastoma cancer stem cells based on biomedical technologies: From theory to experiment (Review).
Bryukhovetskiy I; Ponomarenko A; Lyakhova I; Zaitsev S; Zayats Y; Korneyko M; Eliseikina M; Mischenko P; Shevchenko V; Shanker Sharma H; Sharma A; Khotimchenko Y
Int J Mol Med; 2018 Aug; 42(2):691-702. PubMed ID: 29749540
[TBL] [Abstract][Full Text] [Related]
32. Novel cellular and post-genomic technologies in the treatment of glioblastoma multiforme (Review).
Bryukhovetskiy I; Bryukhovetskiy A; Khotimchenko Y; Mischenko P
Oncol Rep; 2016 Feb; 35(2):639-48. PubMed ID: 26548844
[TBL] [Abstract][Full Text] [Related]
33. Side population is not necessary or sufficient for a cancer stem cell phenotype in glioblastoma multiforme.
Broadley KW; Hunn MK; Farrand KJ; Price KM; Grasso C; Miller RJ; Hermans IF; McConnell MJ
Stem Cells; 2011 Mar; 29(3):452-61. PubMed ID: 21425408
[TBL] [Abstract][Full Text] [Related]
34. Drug repurposing towards targeting cancer stem cells in pediatric brain tumors.
Bahmad HF; Elajami MK; El Zarif T; Bou-Gharios J; Abou-Antoun T; Abou-Kheir W
Cancer Metastasis Rev; 2020 Mar; 39(1):127-148. PubMed ID: 31919619
[TBL] [Abstract][Full Text] [Related]
35. Novel therapeutics and drug-delivery approaches in the modulation of glioblastoma stem cell resistance.
Smiley SB; Zarrinmayeh H; Das SK; Pollok KE; Vannier MW; Veronesi MC
Ther Deliv; 2022 Apr; 13(4):249-273. PubMed ID: 35615860
[TBL] [Abstract][Full Text] [Related]
36. Therapy-resistant tumor microvascular endothelial cells contribute to treatment failure in glioblastoma multiforme.
Borovski T; Beke P; van Tellingen O; Rodermond HM; Verhoeff JJ; Lascano V; Daalhuisen JB; Medema JP; Sprick MR
Oncogene; 2013 Mar; 32(12):1539-48. PubMed ID: 22614016
[TBL] [Abstract][Full Text] [Related]
37. The role of cancer stem cells in glioblastoma.
Sundar SJ; Hsieh JK; Manjila S; Lathia JD; Sloan A
Neurosurg Focus; 2014 Dec; 37(6):E6. PubMed ID: 25434391
[TBL] [Abstract][Full Text] [Related]
38. New molecules and old drugs as emerging approaches to selectively target human glioblastoma cancer stem cells.
Würth R; Barbieri F; Florio T
Biomed Res Int; 2014; 2014():126586. PubMed ID: 24527434
[TBL] [Abstract][Full Text] [Related]
39. [Progress in the study of brain tumor stem cells as treatment targets].
Hide T; Kuratsu J
Brain Nerve; 2009 Jul; 61(7):781-9. PubMed ID: 19618855
[TBL] [Abstract][Full Text] [Related]
40. Chemoresistance in high-grade gliomas: relevance of adenosine signalling in stem-like cells of glioblastoma multiforme.
Garrido W; Rocha JD; Jaramillo C; Fernandez K; Oyarzun C; San Martin R; Quezada C
Curr Drug Targets; 2014; 15(10):931-42. PubMed ID: 25174341
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
